DNA methylation as a new tool for the differential diagnosis between T-LBL and lymphocyte-rich thymoma.
DNA methylation
MS‐MLPA
T‐LBL
biomarker
diagnosis
epigenetic
prediction model
thymoma
Journal
The Journal of pathology
ISSN: 1096-9896
Titre abrégé: J Pathol
Pays: England
ID NLM: 0204634
Informations de publication
Date de publication:
27 Sep 2024
27 Sep 2024
Historique:
revised:
31
07
2024
received:
20
10
2023
accepted:
06
08
2024
medline:
27
9
2024
pubmed:
27
9
2024
entrez:
27
9
2024
Statut:
aheadofprint
Résumé
T-lymphoblastic lymphoma (T-LBL) and thymoma are two rare primary tumors of the thymus deriving either from T-cell precursors or from thymic epithelial cells, respectively. Some thymoma subtypes (AB, B1, and B2) display numerous reactive terminal deoxynucleotidyl transferase-positive (TdT
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : INCA (Institut National du Cancer)
Informations de copyright
© 2024 The Author(s). The Journal of Pathology published by John Wiley & Sons Ltd on behalf of The Pathological Society of Great Britain and Ireland.
Références
Marx A, Chan JKC, Chalabreysse L, et al. The 2021 WHO classification of tumors of the thymus and mediastinum: what is new in thymic epithelial, germ cell, and mesenchymal tumors? J Thorac Oncol 2022; 17: 200–213.
Adam P, Hakroush S, Hofmann I, et al. Thymoma with loss of keratin expression (and giant cells): a potential diagnostic pitfall. Virchows Arch 2014; 465: 313–320.
Boddu P, Thakral B, Alhuraiji A, et al. Distinguishing thymoma from T‐lymphoblastic leukaemia/lymphoma: a case‐based evaluation. J Clin Pathol 2019; 72: 251–257.
de Jong WK, Blaauwgeers JLG, Schaapveld M, et al. Thymic epithelial tumours: a population‐based study of the incidence, diagnostic procedures and therapy. Eur J Cancer 2008; 44: 123–130.
Hsu C‐H, Chan JK, Yin C‐H, et al. Trends in the incidence of thymoma, thymic carcinoma, and thymic neuroendocrine tumor in the United States. PLoS One 2019; 14: e0227197.
Girard N, Ruffini E, Marx A, et al. Thymic epithelial tumours: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow‐up. Ann Oncol 2015; 26: v40–v55.
Lepretre S, Touzart A, Vermeulin T, et al. Pediatric‐like acute lymphoblastic leukemia therapy in adults with lymphoblastic lymphoma: the GRAALL‐LYSA LL03 study. J Clin Oncol 2016; 34: 572–580.
Callens C, Baleydier F, Lengline E, et al. Clinical impact of NOTCH1 and/or FBXW7 mutations, FLASH deletion, and TCR status in pediatric T‐cell lymphoblastic lymphoma. J Clin Oncol 2012; 30: 1966–1973.
Molina TJ, Bluthgen MV, Chalabreysse L, et al. Impact of expert pathologic review of thymic epithelial tumours on diagnosis and management in a real‐life setting: a RYTHMIC study. Eur J Cancer 2021; 143: 158–167.
Villarese P, Abdo C, Bertrand M, et al. One‐step next‐generation sequencing of immunoglobulin and T‐cell receptor gene recombinations for MRD marker identification in acute lymphoblastic leukemia. Methods Mol Biol 2022; 2453: 43–59.
Armand M, Derrieux C, Beldjord K, et al. A new and simple TRG multiplex PCR assay for assessment of T‐cell clonality: a comparative study from the EuroClonality Consortium. Hemasphere 2019; 3: e255.
van Dongen JJM, Langerak AW, Brüggemann M, et al. Design and standardization of PCR primers and protocols for detection of clonal immunoglobulin and T‐cell receptor gene recombinations in suspect lymphoproliferations: report of the BIOMED‐2 Concerted Action BMH4‐CT98‐3936. Leukemia 2003; 17: 2257–2317.
Giraud M, Salson M, Duez M, et al. Fast multiclonal clusterization of V(D)J recombinations from high‐throughput sequencing. BMC Genomics 2014; 15: 409.
Touzart A, Boissel N, Belhocine M, et al. Low level CpG island promoter methylation predicts a poor outcome in adult T‐cell acute lymphoblastic leukemia. Haematologica 2020; 105: 1575–1581.
Touzart A, Mayakonda A, Smith C, et al. Epigenetic analysis of patients with T‐ALL identifies poor outcomes and a hypomethylating agent‐responsive subgroup. Sci Transl Med 2021; 13: eabc4834.
Jevremovic D, Roden AC, Ketterling RP, et al. LMO2 is a specific marker of T‐lymphoblastic leukemia/lymphoma. Am J Clin Pathol 2016; 145: 180–190.
Latchmansingh K‐A, Wang X, Verdun RE, et al. LMO2 expression is frequent in T‐lymphoblastic leukemia and correlates with survival, regardless of T‐cell stage. Mod Pathol 2022; 35: 1220–1226.
Morishima T, Krahl A‐C, Nasri M, et al. LMO2 activation by deacetylation is indispensable for hematopoiesis and T‐ALL leukemogenesis. Blood 2019; 134: 1159–1175.
Touzart A, Lengliné E, Latiri M, et al. Epigenetic silencing affects l‐asparaginase sensitivity and predicts outcome in T‐ALL. Clin Cancer Res 2019; 25: 2483–2493.
Choudhury SR, Dutta S, Bhaduri U, et al. LncRNA Hmrhl regulates expression of cancer related genes in chronic myelogenous leukemia through chromatin association. NAR Cancer 2021; 3: zcab042.
van der Zee RP, van Noesel CJM, Martin I, et al. DNA methylation markers have universal prognostic value for anal cancer risk in HIV‐negative and HIV‐positive individuals. Mol Oncol 2021; 15: 3024–3036.
Lak NSM, Voormanns TL, Zappeij‐Kannegieter L, et al. Improving risk stratification for pediatric patients with rhabdomyosarcoma by molecular detection of disseminated disease. Clin Cancer Res 2021; 27: 5576–5585.
van den Helder R, Wever BMM, van Trommel NE, et al. Non‐invasive detection of endometrial cancer by DNA methylation analysis in urine. Clin Epigenetics 2020; 12: 165.
Zhang Y‐W, Ma J, Shi C‐T, et al. Roles and correlation of FOXA1 and ZIC1 in breast cancer. Curr Probl Cancer 2020; 44: 100559.
Dick S, Verhoef L, De Strooper LM, et al. Evaluation of six methylation markers derived from genome‐wide screens for detection of cervical precancer and cancer. Epigenomics 2020; 12: 1569–1578.
Ge Q, Hu Y, He J, et al. Zic1 suppresses gastric cancer metastasis by regulating Wnt/β‐catenin signaling and epithelial–mesenchymal transition. FASEB J 2020; 34: 2161–2172.
Fu J‐Q, Chen Z, Hu Y‐J, et al. A single factor induces neuronal differentiation to suppress glioma cell growth. CNS Neurosci Ther 2019; 25: 486–495.
Wang Y‐Y, Jiang J‐X, Ma H, et al. Role of ZIC1 methylation in hepatocellular carcinoma and its clinical significance. Tumour Biol 2014; 35: 7429–7433.
Rodríguez‐Rodero S, Fernández AF, Fernández‐Morera JL, et al. DNA methylation signatures identify biologically distinct thyroid cancer subtypes. J Clin Endocrinol Metab 2013; 98: 2811–2821.
Uribe ML, Dahlhoff M, Batra RN, et al. TSHZ2 is an EGF‐regulated tumor suppressor that binds to the cytokinesis regulator PRC1 and inhibits metastasis. Sci Signal 2021; 14: eabe6156.
Zhao S, Guo X, Mizutani K‐I, et al. Overexpression of Teashirt Homolog 2 suppresses cell proliferation and predicts the favorable survival of lung adenocarcinoma. Int J Med Sci 2021; 18: 1980–1989.
Xie W, Du Z, Chen Y, et al. Identification of metastasis‐associated genes in triple‐negative breast cancer using weighted gene co‐expression network analysis. Evol Bioinform Online 2020; 16: 1176934320954868.
Moon SU, Kim JH, Woo HG. Tumor suppressor RBM24 inhibits nuclear translocation of CTNNB1 and TP63 expression in liver cancer cells. Oncol Lett 2021; 22: 674.
Hua W‐F, Zhong Q, Xia T‐L, et al. RBM24 suppresses cancer progression by upregulating miR‐25 to target MALAT1 in nasopharyngeal carcinoma. Cell Death Dis 2016; 7: e2352.
Xia RM, Liu T, Li WG, et al. RNA‐binding protein RBM24 represses colorectal tumourigenesis by stabilising PTEN mRNA. Clin Transl Med 2021; 11: e383.
Min J‐W, Koh Y, Kim D‐Y, et al. Identification of novel functional variants of SIN3A and SRSF1 among somatic variants in acute myeloid leukemia patients. Mol Cells 2018; 41: 465–475.
Torres‐Martín M, Kusak ME, Isla A, et al. Whole exome sequencing in a case of sporadic multiple meningioma reveals shared NF2, FAM109B, and TPRXL mutations, together with unique SMARCB1 alterations in a subset of tumor nodules. Cancer Genet 2015; 208: 327–332.
Zhou Z‐J, Luo C‐B, Xin H‐Y, et al. MACROD2 deficiency promotes hepatocellular carcinoma growth and metastasis by activating GSK‐3β/β‐catenin signaling. NPJ Genomic Med 2020; 5: 15.
Sakthianandeswaren A, Parsons MJ, Mouradov D, et al. MACROD2 deletions cause impaired PARP1 activity and chromosome instability in colorectal cancer. Oncotarget 2018; 9: 33056–33058.
Hu N, Kadota M, Liu H, et al. Genomic landscape of somatic alterations in esophageal squamous cell carcinoma and gastric cancer. Cancer Res 2016; 76: 1714–1723.
Chen C, Bartenhagen C, Gombert M, et al. Next‐generation‐sequencing of recurrent childhood high hyperdiploid acute lymphoblastic leukemia reveals mutations typically associated with high risk patients. Leuk Res 2015; 39: 990–1001.